Institute of Biophysics and Cell Engineering

http://ibp.org.by/  
220072 Minsk, Akademicheskaya str. 27

Biomedical cell product "Skin Tissue Equivalent"

COUNTRY OF ORIGIN

IDENTIFIER

BO4355

PUBLISHED

2021-10-20

LAST UPDATE

2021-10-20

DEADLINE

Linked profile in other language
Responsible
Elena Кniazeva
+375 17 251 5357
kniazeva@ibp.org.by
Summary
The Institute has developed a biomedical cell product "Skin Tissue Equivalent" (STE) and a method of cell therapy in combustiology, surgery, etc. with its application. The Institute offers services for the treatment of diseases using the developed STE under an outsourcing agreement.
Description
Skin Tissue Equivalent (STE) is intended to restore the skin in patients with extensive and deep burns, as well as in patients with trophic ulcers, bedsores, and other types of chronic wounds.

The dermal component is based on a three-dimensional biodegradable collagen matrix, which is necessary for cell migration and contains layer-by-layer fibroblasts and keratinocytes. The final treatment form of STE is formed directly on the wound.

Local transplantation of STEs makes it possible to create a high initial concentration of functionally active cells on the wound surface. STE provides the synthesis of cytokines and extracellular matrix components, stimulates wound vascularization, proliferation, and differentiation of the patient's own skin cells. Fibroblasts and keratinocytes in the STE participate in the formation of a full-fledged skin.

The Institute offers services for the treatment of diseases using the developed biomedical cell product "Skin Tissue Equivalent" under an outsourcing agreement.
Advantages and Innovations
The use of STE in clinical practice increases the effectiveness of existing treatment methods, does not cause complications and side effects.
Stage of development
Already on the market
Funding source
State budged
IPR status
Secret know-how
Sector group
Healthcare

Organization information

Type
R&D institution
Year established
1973
NACE keywords
M.72.11 - Research and experimental development on biotechnology
Q.86.90 - Other human health activities
Already engaged in transnational cooperation
Yes
Additional comments
Over the past 10 years, the Institute has carried out a number of international contracts and agreements within the framework of the Framework Programs of the European Union, as well as with leading research centers, foundations, societies:
FP7-HEALTH-2007-4.1-8 «Promotion and facilitation of international cooperation with Eastern European and Central Asian Countries» (EECAlink, Nr. 223359), 2009-2011;

UNESCO № IAP 3240246593/011/027-Minsk « Science Academies in the Central and Eastern Europe and their Role in Knowledge-based Society», 2010-2011;

FP7-PEAPLE-2012-IRSES «Development of Nanotechnology based Biosensors for Agriculture» (PIRSES-GA-2012-318520), 2012-2016;

FP7-PEAPLE-2012-IRSES «EU-Belarus-Russia Network in Nanomaterials-Driven Anti-Cancer Gene Therapy» (PIRSES-GA-2012-316730), 2013-2017;

FP7-PEOPLE-2011-IIF-299194 «Optical real-time imaging of inhibitory GABAA receptors activity using chimeric GABA channel subunit» («ImagingGABA» Nr 299194) 2013-2015;

«INNOVIMMUNE: Baltic Platform for Innovative Immunotherapies», Nr 19806/2016,2016-2018;

NAWA IAP «Strengthening and spreading international partnership activities of the Faculty of Biology and Environmental Protection for interdisciplinary research and innovation of the University of Lodz» (№ PPI/APM/2018/1/00007/U/001) 2019-2020;

H2020-MSCA-RISE-2017 «Novel 1D photonic metal oxide nanostructures for early stage cancer detection» («CanBioSe», Nr 778157) 2018-2021:

The International Organization for Neurochemistry (ISN); Takeda Science Foundation; The Karpilo-Landau Society; Swiss National Science Foundation; University of Eastern Finland; World Federation of Scientists to Support Research, etc.
Languages spoken
English
Russian

Information about partnership

Type of partnership considered
Outsourcing agreement
Type and role of partner sought
Consumers interested in receiving services for the treatment of diseases using the developed biomedical cell product "Skin Tissue Equivalent" within the framework of an outsourcing agreement.
Type and size of partner sought
251-500
SME 11-50
SME 51-250

Attachments

Views: 1605
Statistics since 20.10.2021 17:08:26